127 related articles for article (PubMed ID: 26649873)
21. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
[TBL] [Abstract][Full Text] [Related]
22. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
McTavish D; Campoli-Richards D; Sorkin EM
Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Bauman JL; Talbert RL
J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
[TBL] [Abstract][Full Text] [Related]
24. [Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Ozova EM; Kiiakbaev GK; Kobalava ZhD; Moiseev VS
Kardiologiia; 2011; 51(4):39-46. PubMed ID: 21623719
[No Abstract] [Full Text] [Related]
25. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
[TBL] [Abstract][Full Text] [Related]
26. Role of carvedilol controlled-release in cardiovascular disease.
Fonarow GC
Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
[TBL] [Abstract][Full Text] [Related]
27. Clinical pharmacokinetics and pharmacodynamics of carvedilol.
Morgan T
Clin Pharmacokinet; 1994 May; 26(5):335-46. PubMed ID: 7914479
[TBL] [Abstract][Full Text] [Related]
28. Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats.
Kim MS; Baek IH
Eur J Pharm Sci; 2018 Jan; 111():13-19. PubMed ID: 28942006
[TBL] [Abstract][Full Text] [Related]
29. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
[TBL] [Abstract][Full Text] [Related]
30. Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients.
Kaijser M; Johnsson C; Zezina L; Backman U; Dimény E; Fellström B
Clin Transplant; 1997 Dec; 11(6):577-81. PubMed ID: 9408688
[TBL] [Abstract][Full Text] [Related]
31. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
Miki S; Masumura H; Kaifu Y; Yuasa S
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
[TBL] [Abstract][Full Text] [Related]
33. Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.
Rau T; Düngen HD; Edelmann F; Waagstein F; Lainščak M; Dimković S; Apostolović S; Nešković AN; Haverkamp W; Gelbrich G; Eschenhagen T
Clin Pharmacol Ther; 2012 Jul; 92(1):21-8. PubMed ID: 22617224
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
Liu XY; Wang BJ; Yuan GY; Guo RC
Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
[TBL] [Abstract][Full Text] [Related]
35. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.
Kim YH; Choi HY; Noh YH; Lee SH; Lim HS; Kim C; Bae KS
Drug Des Devel Ther; 2015; 9():2911-8. PubMed ID: 26089641
[TBL] [Abstract][Full Text] [Related]
36. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
Louis WJ; McNeil JJ; Workman BS; Drummer OH; Conway EL
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S89-93. PubMed ID: 2454376
[TBL] [Abstract][Full Text] [Related]
37. In vivo in silico pharmacokinetic simulation studies of carvedilol-loaded nanocapsules using GastroPlus.
George JK; Singh SK; Verma PR
Ther Deliv; 2016; 7(5):305-18. PubMed ID: 27075951
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and pharmacodynamic properties of carvedilol in fructose hypertensive rats.
Bertera F; Di Verniero CA; Mayer MA; Chiappetta D; Buontempo F; Polizio AH; Taira CA; Höcht C
Xenobiotica; 2012 Feb; 42(2):206-19. PubMed ID: 21892881
[TBL] [Abstract][Full Text] [Related]
39. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
Abshagen U
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
[TBL] [Abstract][Full Text] [Related]
40. Assessment of sex differences in Pharmacokinetics of carvedilol in human.
Abbas M; Khan AM; Riffat S; Tipu MY; Nawaz HA; Usman M
Pak J Pharm Sci; 2014 Sep; 27(5):1265-9. PubMed ID: 25176381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
